Jun 2026 (Q2 FY26) — Aug 11, 2026
Taysha Gene Therapies Q2 FY26 — Clinical Progress and Strengthened Financial Position
Read the full callTaysha Gene Therapies (TSHA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Taysha Gene Therapies earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | −100.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -46.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.73 +6.27% · +$0.22
Performance −27.7% 1Y
1Y: $5.16 on 14 Oct 2025 → $3.73. High $6.98 (6 May 2026), low $3.51 (14 Oct 2026).
- Previous close
- $3.51
- 52-week range
- $3.51 – $6.98
- One year
- −30.15%
Overview
- Symbol
- TSHA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Taysha Gene Therapies earnings calls (TSHA)
Financials
What the filings say
Net profit, year on year: −73% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 2 | 2 | 2 | 0 | 5 | 0 | 0 |
| Operating profit | -26 | -20 | -21 | -27 | -34 | -28 | -43 | -47 |
| Operating margin | −1448.4% | −985.8% | −930.5% | −1347.1% | — | −516.0% | — | — |
| Other income | 0 | 1 | -0 | -0 | 1 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -26 | -19 | -22 | -27 | -33 | -28 | -42 | -47 |
| EPS ($ per share) | -0.10 | — | -0.08 | -0.09 | -0.09 | — | -0.12 | -0.13 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 | 0 | 0 |
| Reserves | -61 | -236 | -401 | -513 | -602 | -711 |
| Total liabilities | 8 | 119 | 125 | 98 | 89 | 96 |
| Fixed assets | 0 | 51 | 15 | 11 | 7 | 7 |
| Total assets | 259 | 214 | 126 | 173 | 160 | 343 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -31 | -117 | -88 | -73 | -81 | -93 |
| Cash from investing | -9 | -22 | -25 | -7 | -0 | -1 |
| Cash from financing | 291 | 39 | 52 | 136 | 77 | 275 |
| Net cash flow | 251 | -100 | -61 | 56 | -5 | 181 |
| Capital expenditure | -0 | -15 | -21 | -4 | -0 | -1 |
| Free cash flow | -31 | -132 | -109 | -77 | -82 | -94 |
Insider filings
25 filings between Nov 28, 2025 and Jul 10, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$6.66M
12 sales by 3 insiders
25% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 7
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Nagendran Sukumar | — | $5.33M | Jul 10, 2026 |
| Nolan Sean P. | — | $840.2K | Jan 26, 2026 |
| Alam Kamran | — | $492.5K | Feb 4, 2026 |
Latest filings (38)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 10, 2026 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 plan | 200,000 | $1.25M |
| Jun 1, 2026 | Stalfort John A III Director | Award | 21,335 | $0 |
| Jun 1, 2026 | Sepp-Lorenzino Laura Director | Award | 21,335 | $0 |
| Jun 1, 2026 | Donenberg Phillip B. Director | Award | 21,335 | $0 |
| Jun 1, 2026 | Long Alison S Director | Award | 21,335 | $0 |
| Apr 10, 2026 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 plan | 19,021 | $32.5K |
| Apr 10, 2026 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 plan | 200,000 | $892.0K |
| Feb 4, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 1,655 | $7.5K |
| Jan 26, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 23,849 | $109.9K |
| Jan 26, 2026 | Nolan Sean P. Chief Executive Officer | Sale | 41,312 | $190.4K |
| Jan 26, 2026 | Nagendran Sukumar President and Head of R&D | Sale | 26,918 | $124.1K |
| Jan 23, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 78,968 | $375.1K |
| Jan 23, 2026 | Nolan Sean P. Chief Executive Officer | Sale | 136,789 | $649.7K |
| Jan 23, 2026 | Nagendran Sukumar President and Head of R&D | Sale | 89,132 | $423.4K |
| Jan 12, 2026 | Alam Kamran CHIEF FINANCIAL OFFICER | Award | 359,000 | $0 |
| Jan 12, 2026 | Nolan Sean P. Chief Executive Officer | Award | 1,008,000 | $0 |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 plan | 111,324 | $77.8K |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 plan | 88,676 | $151.6K |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 plan | 200,000 | $942.0K |
| Jan 12, 2026 | Nagendran Sukumar President and Head of R&D | Award 10b5-1 plan | 427,000 | $0 |
| Dec 1, 2025 | Nagendran Sukumar President and Head of R&D | Option exercise | 260,047 | $444.7K |
| Dec 1, 2025 | Nagendran Sukumar President and Head of R&D | Sale | 260,047 | $1.17M |
| Nov 28, 2025 | Nagendran Sukumar President and Head of R&D | Sale | 110,125 | $523.1K |
| Nov 28, 2025 | Nagendran Sukumar President and Head of R&D | Option exercise | 70,172 | $49.0K |
| Nov 28, 2025 | Nagendran Sukumar President and Head of R&D | Option exercise | 39,953 | $68.3K |
| Sep 10, 2025 | Nagendran Sukumar President and Head of R&D | Option exercise 10b5-1 plan | 41,150 | $28.8K |
| Sep 10, 2025 | Nagendran Sukumar President and Head of R&D | Sale 10b5-1 plan | 200,000 | $646.0K |
| Aug 21, 2025 | Alam Kamran CHIEF FINANCIAL OFFICER | Sale | 54,491 | $155.3K |
| Aug 21, 2025 | Nagendran Sukumar President and Head of R&D | Sale | 57,054 | $162.6K |
| Jun 2, 2025 | Sepp-Lorenzino Laura Director | Award | 56,623 | $0 |
| Jun 2, 2025 | Long Alison S Director | Award | 56,623 | $0 |
| Jun 2, 2025 | Donenberg Phillip B. Director | Award | 56,623 | $0 |
| Jun 2, 2025 | Stalfort John A III Director | Award | 56,623 | $0 |
| May 30, 2025 | Manning Paul B 10% owner | Purchase | 750,000 | $2.06M |
| Mar 11, 2025 | Alam Kamran CHIEF FINANCIAL OFFICER | Tax withheld | 29,843 | $50.4K |
| Jan 2, 2025 | Alam Kamran CHIEF FINANCIAL OFFICER | Award | 431,000 | $0 |
| Jan 2, 2025 | Nagendran Sukumar President and Head of R&D | Award | 324,500 | $0 |
| Jan 2, 2025 | Nolan Sean P. Chief Executive Officer | Award | 892,500 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Taysha Gene Therapies, Inc.
Free account. Everything above stays public.
Write why you follow Taysha Gene Therapies, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading